Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions

Abstract

Since its discovery, myosin-binding protein C (cMyBP-C) has become a protein of interest clinically. With emergence of new methodologies and technologies, the structure and functions of cMyBP-C from different aspects can be studied, enabling us to better understand its involvement in certain cardiac conditions. Studying its kinetics of release and clearance from the circulation and by comparing to other conventional biomarkers, it has been reported that cMyBP-C is eligible to be a novel biomarker for several cardiac conditions. Moreover, studying the genetics and their involvement in pathogenic mechanisms has opened the ideas for potential therapeutic strategies. More and more researches are constantly being done to better understand the role of cMyBP-C in dilated cardiomyopathy (DCM). The importance of cMyBP-C to the heart is still actively being investigated. Its presence is however crucial for sarcomere organization and proper regulation of cardiac contraction during systole and complete relaxation during diastole. Genetic mutation in cMyBP-C has been linked to cardiac conditions including hypertrophic and dilated cardiomyopathies. Around 350 types of mutations have already been documented leading to various cardiac conditions and abnormalities. Analyzing human heart samples has enabled us to better understand the importance of cMyBP-C and how its mutations lead to inherited cardiomyopathies. It is therefore necessary to have an update about the research progress of cMyBP-C in relation to DCM and other cardiac conditions.

Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy

“…Cardiac myosin binding protein-C is a sarcomeric protein with important implications in the regulation of cardiac systolic and diastolic function. Considering that DCM manifests as a deterioration of systolic and diastolic function, more and more studies are being done to better understand MyBP-C implications in patients with dilated cardiomyopathy [ 56 ]. Different MyBP-C genetic defects or an eliciting autoimmune response may lead to dilated cardiomyopathy.…”

Insights into the Novel Cardiac Biomarker in Acute Heart Failure: Mybp-C

“…MyBP-C has been reported in many studies as a novel biomarker in myocardial infarction, which may help to quantify cardiomyocytes injury even more accurately than hs-TnI [35,36]. Also, due to its role in cardiac contraction and relaxation, dephosphorylation and subsequent release into the circulation was observed in patients with heart failure [37][38][39][40][41][42]. Furthermore, MyBP-C has emerged as a potential therapeutic target for the treatment of heart failure.…”